Amygdala Astrocytes Drive Anxiety, Not Just Support It

Glial Cells Step Out of the Shadows

For decades, astrocytes — the star-shaped glial cells that outnumber neurons in the brain — were treated as little more than structural scaffolding. They kept neurons fed, cleared waste, and maintained the chemical environment. Important, yes, but passive. New research published in Neuron is challenging that assumption in a significant way.

A team led by Ciaran Murphy-Royal at the Centre de recherche du Centre hospitalier de l'Université de Montréal (CRCHUM) has demonstrated that astrocytes in the basolateral amygdala (BLA) — the brain's primary fear-processing hub — are not simply responding to neuronal signals. They are actively participating in threat assessment and the regulation of anxiety states. In other words, astrocytes aren't just keeping the lights on. They may be helping decide whether to sound the alarm.

The basolateral amygdala is a region that has long been central to our understanding of fear, trauma, and anxiety disorders. It encodes fear memories, evaluates incoming threat signals, and communicates with the prefrontal cortex to modulate behavioral responses. What Murphy-Royal's team found is that astrocyte activity in this region runs on its own logic — it is not merely a reflection of what neurons are doing. Astrocytes appear to have an independent role in shaping how threatening a stimulus is perceived to be. Read the original coverage at MedicalXpress.

Why This Matters for Ketamine Therapy

This research arrives at a moment when the field of ketamine and esketamine therapy is increasingly moving beyond the simple NMDA receptor narrative. Yes, ketamine blocks NMDA receptors — but that explanation has never fully accounted for the speed, depth, or durability of its antidepressant and anxiolytic effects. Researchers have been searching for the fuller picture, and astrocytes may be part of it.

Ketamine is known to affect glial cells, including astrocytes. Studies have shown that ketamine modulates glutamate reuptake — a process astrocytes are heavily involved in — and influences BDNF signaling pathways that astrocytes help regulate. The new CRCHUM findings add a compelling dimension: if astrocytes in the amygdala are active participants in generating and sustaining anxiety, then treatments that affect astrocyte function could be operating on anxiety at a more fundamental level than previously understood.

This is particularly relevant for patients seeking ketamine treatment for anxiety-predominant presentations, PTSD, or treatment-resistant depression with significant anxious features. The therapeutic window that many patients describe — that rapid dissolution of anticipatory dread or fear-based rumination in the hours and days after an infusion — may have a glial component that we are only beginning to map.

What This Means for Patients and Providers

For patients currently in ketamine therapy or considering it, this research is not a reason to change course — it is a reason to feel more confident that the science underlying these treatments is deepening. Ketamine's effects on anxiety have been documented clinically, but the why has remained somewhat murky. Studies like this one help fill in the biological story.

For providers and prescribers, the findings underscore the importance of considering astrocyte biology when evaluating emerging ketamine formulations, dosing strategies, and adjunct therapies. Protocols that pair ketamine with evidence-based psychotherapy — particularly trauma-focused approaches that target the amygdala's fear-memory circuitry — may be doing more than we realized by engaging a system that now appears to include an active glial component.

There is also a longer arc here worth watching. If astrocytes can be targeted therapeutically — through pharmacology, neurostimulation, or novel biologics — the treatment landscape for anxiety disorders could shift meaningfully in the next decade. Ketamine may turn out to be an early, imprecise tool in what eventually becomes a much more refined approach to modulating glial-neuronal anxiety circuits. Patients and caregivers researching treatment options in 2026 are watching this field evolve in real time.

For now, the practical guidance is this: work with a qualified ketamine provider who understands the neurobiological complexity of what they are treating. The brain's anxiety system is not a single dial to be turned down — it is a distributed network involving neurons, astrocytes, the amygdala, the prefrontal cortex, and more. Treatments that engage that network thoughtfully, with proper integration support, remain the standard worth seeking.